These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 11880741)

  • 1. Use of myeloid colony-stimulating factors in neonates with septicemia.
    Bernstein HM; Calhoun DA; Christensen RD
    Curr Opin Pediatr; 2002 Feb; 14(1):91-4. PubMed ID: 11880741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid colony-stimulating factors: use in the newborn.
    Sreenan C; Osiovich H
    Arch Pediatr Adolesc Med; 1999 Sep; 153(9):984-8. PubMed ID: 10482217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The current role of colony-stimulating factors in prevention and treatment of neonatal sepsis.
    Banerjea MC; Speer CP
    Semin Neonatol; 2002 Aug; 7(4):335-49. PubMed ID: 12401303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of recombinant granulocyte colony-stimulating factor, recombinant human granulocyte-macrophage colony-stimulating factor and placebo for treatment of septic preterm infants.
    Ahmad A; Laborada G; Bussel J; Nesin M
    Pediatr Infect Dis J; 2002 Nov; 21(11):1061-5. PubMed ID: 12442030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial of granulocyte-macrophage colony-stimulating factor in neonates with sepsis and neutropenia.
    Bilgin K; Yaramiş A; Haspolat K; Taş MA; Günbey S; Derman O
    Pediatrics; 2001 Jan; 107(1):36-41. PubMed ID: 11134431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential use of granulocyte colon-stimulating factor and granulocyte-macrophage colony-stimulating factor in neonates.
    Bracho F; Goldman S; Cairo MS
    Curr Opin Hematol; 1998 May; 5(3):215-20. PubMed ID: 9664163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human granulocyte colony-stimulating factor may improve outcome attributable to neonatal sepsis complicated by neutropenia.
    Kocherlakota P; La Gamma EF
    Pediatrics; 1997 Jul; 100(1):E6. PubMed ID: 9200380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human granulocyte colony-stimulating factor in preterm neonates with sepsis and relative neutropenia: a randomized, single-blind, non-placebo-controlled trial.
    Gathwala G; Walia M; Bala H; Singh S
    J Trop Pediatr; 2012 Feb; 58(1):12-8. PubMed ID: 21296862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hematopoietic growth factors in prevention and therapy of infectious complications in premature and newborn infants].
    Lehrnbecher T
    Z Geburtshilfe Neonatol; 2001; 205(5):167-73. PubMed ID: 11727663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The in vitro effects of granulocyte and granulocyte-macrophage colony-stimulating factor on interleukin-3-dependent proliferation of human neonatal circulating progenitor cells.
    Bedford Russell AR; Davies EG; Gibson FM; Gordon-Smith EC
    Pediatr Res; 1995 May; 37(5):630-3. PubMed ID: 7541523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of recombinant human granulocyte colony stimulating factor (rhG-CSF) for the treatment of neonates in presumed sepsis with neutropenia.
    Khan TH; Shahidullah M; Mannan MA; Nahar N
    Mymensingh Med J; 2012 Jul; 21(3):469-74. PubMed ID: 22828545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Administration of recombinant human granulocyte-colony stimulating factor to septic neonates induces neutrophilia and enhances the neutrophil respiratory burst and beta2 integrin expression. Results of a randomized controlled trial.
    Drossou-Agakidou V; Kanakoudi-Tsakalidou F; Sarafidis K; Taparkou A; Tzimouli V; Tsandali H; Kremenopoulos G
    Eur J Pediatr; 1998 Jul; 157(7):583-8. PubMed ID: 9686822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary report: rhG-CSF may reduce the incidence of neonatal sepsis in prolonged preeclampsia-associated neutropenia.
    Kocherlakota P; La Gamma EF
    Pediatrics; 1998 Nov; 102(5):1107-11. PubMed ID: 9794941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo effect of recombinant human granulocyte colony-stimulating factor on phagocytic function and oxidative burst activity in septic neutropenic neonates.
    Ahmad M; Fleit HB; Golightly MG; La Gamma EF
    Biol Neonate; 2004; 86(1):48-54. PubMed ID: 15057022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of neutrophil and monocyte function by microbicidal cell-kill assay in patients with cancer receiving granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, or no cytokine after cytotoxic chemotherapy: a phase II trial.
    Nemunaitis J; Cox J; Meyer W; Courtney A; Hanson T; Green-Weaver C; Agosti J
    Am J Clin Oncol; 1998 Jun; 21(3):308-12. PubMed ID: 9626806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor have differential effects on neonatal and adult neutrophil survival and function.
    Molloy EJ; O'Neill AJ; Grantham JJ; Sheridan-Pereira M; Fitzpatrick JM; Webb DW; Watson RW
    Pediatr Res; 2005 Jun; 57(6):806-12. PubMed ID: 15718363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A trial of recombinant human granulocyte colony stimulating factor for the treatment of very low birthweight infants with presumed sepsis and neutropenia.
    Bedford Russell AR; Emmerson AJ; Wilkinson N; Chant T; Sweet DG; Halliday HL; Holland B; Davies EG
    Arch Dis Child Fetal Neonatal Ed; 2001 May; 84(3):F172-6. PubMed ID: 11320043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of recombinant human granulocyte colony stimulating factor and granulocyte-monocyte colony stimulating factor on in vitro hemopoiesis in the myelodysplastic syndromes.
    Nagler A; Ginzton N; Negrin R; Bang D; Donlon T; Greenberg P
    Leukemia; 1990 Mar; 4(3):193-202. PubMed ID: 1690318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granulocyte-macrophage colony stimulating factor administered as prophylaxis for reduction of sepsis in extremely preterm, small for gestational age neonates (the PROGRAMS trial): a single-blind, multicentre, randomised controlled trial.
    Carr R; Brocklehurst P; Doré CJ; Modi N
    Lancet; 2009 Jan; 373(9659):226-33. PubMed ID: 19150703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloid hematopoietic growth factors and their role in prevention and/or treatment of neonatal sepsis.
    Parravicini E; van de Ven C; Anderson L; Cairo MS
    Transfus Med Rev; 2002 Jan; 16(1):11-24. PubMed ID: 11788926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.